Kornimate/medical-research-clean huggingface dataset:
the effect of exercise training on skeletal muscle metabolism in peripheral artery disease (pad)

Conditions: Claudication

Summary: specific aim 1: to test the hypothesis that subjects with pad and intermittent claudication have altered expression of genes that regulate skeletal muscle metabolism. specific aim 2: to test the hypothesis that exercise training improves calf skeletal muscle insulin resistance and genes that regulate skeletal muscle metabolic function in pad patients with intermittent claudication.


Eligibility criteria:
inclusion criteria: * claudication symptoms * abi ≤ 0.9 in the symptomatic leg exclusion criteria: * diabetes * impaired fasting glucose * peripheral vascular intervention within the prior six months * recent unstable angina * myocardial infarction or stroke within the prior six months * changes to their hmg-coa reductase inhibitor (statin)within the past three months * changes to pentoxifylline and/or cilostazol regimen within the past three months or anticipated to be necessary during the study * are on coumadin * exercise limitations for reasons other than intermittent claudication (such as congestive heart failure, angina, chronic lung disease, or other disorders affecting the limb such as arthritis or neuropathy) * rest pain or ulcers due to critical limb ischemia * lower extremity amputation

Keywords: claudication peripheral artery disease pad
terazosin for dementia with lewy bodies

Conditions: Dementia With Lewy Bodies

Summary: the tz-dlb trial will be a 3:2 (active:placebo) randomized, double-blind, placebo-controlled pilot trial to evaluate the tolerability of terazosin for the treatment of dementia with lewy bodies.

this will be a single center, randomized, double-blind, placebo-controlled, pilot study to assess the tolerability of terazosin (tz) at 1 and 5 milligrams (mg) daily for patients with dlb. the primary goal of this study is to assess the tolerability of tz in patients with dlb. this is a pilot study and is not powered to assess efficacy of this medication. our hope is that this study will guide future studies of this (and similar) medications for the disease modification of dlb. this study is also aimed to learn more about how patients with produce and use energy and if tz can help to reverse energy deficits that appear in dlb.

Eligibility criteria:
inclusion criteria: * men or women with the diagnosis of dementia with lewy bodies per 2017 dlb consortium criteria. * baseline moca 18 or above. on stable achei and/or memantine treatment regimen for ≥4 weeks prior to baseline. exclusion criteria: * subjects unwilling or unable to give informed consent * no confounding acute or unstable medical, psychiatric, orthopedic condition. subjects who have hypertension, diabetes mellitus, depression, or other common age-related illness will be included if their disease under control with stable treatment regimen for at least 30 days. * orthostatic hypotension defined as symptomatic decrease in bp \> 20mmhg systolic or \> 10mmhg diastolic on supine to sitting or standing, or a sitting blood pressure of ≤90/60. * clinically significant traumatic brain injury or post-traumatic stress disorder * presence of other known medical comorbidities that in the investigator's opinion would compromise participation in the study * psychiatric comorbidities including major depression, bipolar affective disorder, or other mental health disorders that are sufficiently severe to increase adverse event risk or impact neurology assessment in the opinion of the responsible site principal investigator. subjects with clinically significant depression as determined by a beck depression inventory score greater than 21 at the screening visit. current suicidal ideation within one year prior to the baseline visit as evidenced by answering "yes" to questions 4 or 5 on the suicidal ideation portion of the columbia-suicide severity rating scale (c-ssrs) if the participant has a beck anxiety score greater than 22 at the initial screening visit. * use of investigational drugs within 30 days before screening * subjects have to be on a stable regimen of central nervous system acting medications (benzodiazepines, antidepressants, hypnotics) for 30 days prior to the baseline visit * use of doxazosin, alfuzosin, prazosin, or tamsulosin * for female participant, pregnancy, or plans for child-bearing during study period * participant is restricted from traveling to and from the study site
evaluating an hiv risk screening tool for orphans and vulnerable children in tanzania

Conditions: Pediatric HIV Infection

Summary: the goal of the research was to evaluate the performance of items within the kizazi kipya (k2) orphan and vulnerable children (ovc) hiv risk screening tool in identifying hiv-positive children, to optimize an hiv screening tool for ovc and children and adolescents in facility settings and to assess the feasibility and acceptability of home-based hiv risk screening and testing.

under the ongoing community-based kizazi kipya (k2) ovc project, program staff currently administer a 13-item hiv risk screening tool to all k2 program beneficiaries, and refers those who screen positive to facility-based hiv testing. a subset of this 13-item tool is a module of four items that had previously been used as a standalone four-question screening tool in facilities in zimbabwe. the primary objectives of this study are as follows. 1. to evaluate the performance of a lay cadre-administered four-item subset of the k2 hiv risk screening tool that matches the zimbabwe evidence-based tool in predicting the hiv status of vulnerable children/adolescents represented by two populations: (a) k2 ovc beneficiaries and (b) children/adolescents attending health facilities. 2. to identify additional items in the k2 hiv risk screening tool that could be added to the four-question subset to improve the tool's performance. 3. to assess fidelity to the administration of the ovc hiv screening tool items through structured observations of community case workers in the k2 program. 4. to assess the acceptability of ovc hiv risk screening and testing implemented in the community among ovc beneficiaries in the k2 program. 5. to assess the acceptability and feasibility of integrating the ovc hiv screening tool with hiv testing among ovc community case workers in the k2 program.

Eligibility criteria:
children and adolescents and their caregivers: inclusion criteria: * living in a household deemed to be at elevated hiv risk based on previously identified risk criteria * attending a study health facility in two regions of tanzania * age 2-19 years exclusion criteria: * previously tested hiv-positive * history of antiretroviral treatment (art) * unable or unwilling to be consented * age 5-19 years old, tested negative in past 6 months, and having no reported exposure to hiv through sexual contact (consensual, abuse) or through blood transfusion/needle injury. community care workers: inclusion criteria: * conducting hiv risk screening in ovc households as part of their role in the kizazi kipya project in the subset of study districts where structured observations and focus group discussions were conducted exclusion criteria: * unwilling to consent to the study

Keywords: hiv screen tool orphans and vulnerable children tanzania
functional medical imaging quantization in prostate cancer

Conditions: Prostate Cancer

Summary: prostate cancer is the most common cancer in men over 50 years old and the third leading cause of cancer death. because of the variety of prostate cancers, different treatments exist. several criteria guide this management in daily practice: psa level; tnm stage (digital rectal examination, trans-rectal ultrasound and classical visual imaging) and pathological differentiation with the gleason score, to which can be added other prognostic criteria: growth and doubling time of the serum psa, number of positive biopsies and percentage of cancer lesions by biopsy. functional imaging by pet and mri is increasingly used in daily clinical practice to characterize prostate cancer, either during initial discovery or during recurrence. in this context, it is the qualitative visual analysis that is mainly used. quantitative image analysis could add new criteria to guide patient management. consequently, the objective of this study were: * optimization of 18f-choline pet/ct acquisition in prostate cancer * comparison the quantitative parameters obtained by 18f-choline pet / ct and both perfusion mri and histological parameters.


Eligibility criteria:
inclusion criteria: patients with prostate cancer histologically proven included in brest university hospital between 01/07/2012 and 01/10/2015 and underwent f-choline pet/ct and pelvic mri patient consent exclusion criteria: no lesion on dynamic acquisition on pet/ct and/or on pelvic mri

Keywords: prostate cancer fcholine positron emission tomography mri
the northern ireland haemodialysis vascular access database

Conditions: Hemodialysis Access Failure; Arteriovenous Fistula

Summary: this is database designed to explore clinical outcomes related to vascular assess in the population of northern ireland with ckd stage 5 and end-stage renal failure.

vascular access is the conduit by which blood is transferred from the patient to the dialysis machine and back to the patient during therapy. there are three types of vascular access: arteriovenous fistulas (avf), central venous catheters (cvc) and arteriovenous grafts (avg). avfs are associated with the best patient survival in individuals undergoing dialysis therapy. however, up 30-50% of avfs thrombose or fail to mature sufficiently to support dialysis. the aim of this database is to further research in the area of avf outcomes using routinely collected clinical data..

Eligibility criteria:
inclusion criteria: * individuals attending nephrology undergoing avfcreation between january 2009 and december 2019 in a single centre (belfast city hospital exclusion criteria: * none
alcohol, marijuana, and risky sex: group interventions with detained adolescents

Conditions: Risk Reduction Behavior; Health Behavior; Sexual Behavior; Adolescent Behavior; Cannabis

Summary: this research is studying behaviors that young people engage in that may place them at risk for contracting a sexually transmitted disease like hiv/aids, and what kind of educational program works best to reduce these risky behaviors.

during baseline assessment, a computer questionnaire is administered, including questions about participants' attitudes, beliefs, and behaviors regarding sexual behavior, condom use, and drug use. a saliva sample is provided as well. a "time-line follow-back" is conducted, noting on which days certain activities occurred, such as sexual intercourse, alcohol use, marijuana use, and cigarette use. a urine sample is also collected in order to test for the std's chlamydia and gonorrhea (if results are positive, we schedule a meeting with the participant to administer medication to treat the std). in the second session, a 3-hour interventional health class is held with groups of same-gender participants. there are 3 different health classes (one focusing just on sex risk reduction, one focusing on sex and alcohol risk reduction, and one focusing on sex, alcohol, and marijuana risk reduction); participants are randomly assigned to one. participants are contacted 3 months after the intervention, 6 months after, 9 months after, and 12 months after, in order to meet. these meetings entail completing another time-line follow-back and completing another questionnaire. at the final 12 month meeting, we collect another urine sample to again test for chlamydia and gonorrhea. as before, if results are positive, we schedule a meeting with the participant to administer medical treatment.

Eligibility criteria:
inclusion criteria: * ages 14-18 * involved in juvenile justice system (living in the detention center when recruited) exclusion criteria: * currently taking anti-psychotics * involved in similar intervention-based study (2 similar studies being conducted simultaneously by this lab)
stellate ganglion block: a breakthrough treatment for post-stroke pharyngeal dysphagia

Conditions: Dysphagia; Stellate Ganglion Block

Summary: this was a multicenter randomized controlled study. 66 post-stroke patients with pharyngeal dysphagia were randomly allocated to the observation group (n=33) or the control group (n=33). both groups were provided with comprehensive rehabilitation including routine rehabilitation and swallowing function training. besides, the observation group additionally underwent the stellate ganglion block (sgb). at admission and after 20-day treatment, kubota water swallowing test, video fluoroscopic swallowing study (vfss), and rosenbek penetration-aspiration scale (pas) were used to assess swallowing function.

dysphagia is a frequent and potentially serious complication of stroke. however, there is no effective measure for the treatment of pharyngeal dysphagia in stroke patients. this study aims to explore the efficacy of stellate ganglion block in post-stroke pharyngeal dysphagic patients who received comprehensive rehabilitation. this was a multicenter randomized controlled study. 66 post-stroke patients with pharyngeal dysphagia were randomly allocated to the observation group (n=33) or the control group (n=33). both groups were provided with comprehensive rehabilitation including routine rehabilitation and swallowing function training. besides, the observation group additionally underwent the stellate ganglion block (sgb). at admission and after 20-day treatment, kubota water swallowing test, video fluoroscopic swallowing study (vfss), and rosenbek penetration-aspiration scale (pas) were used to assess swallowing function.

Eligibility criteria:
inclusion criteria: * age between 30 and 80 years; * new-onset stroke, confirmed by head ct or mri; * the course of disease between 1 to 6 months; * with pharyngeal dysphagia shown by vfss; * stable vital signs; * voluntary participation in the study. exclusion criteria: * allergy to lidocaine injection or vitamin b12 injection; * severe cognitive impairment; * coagulation disorders; * severe dysfunction of organs including heart, lungs, kidney, liver, etc.; * complicated with other neurological diseases; * with severe oral dysphagia (results of the vfss oral phase as 2 or 3 points); * dysphagia caused by other diseases or reasons.

Keywords: stellate ganglion block pharyngeal dysphagia stroke rehabilitation swallowing disorder
headache in undergraduate students and biopsychosocial status

Conditions: Headache Disorders, Primary; Prevalence; Migraine; Student; Psychosocial Problem

Summary: the primary aim of this study was to determine the prevalence of headache in undergraduate students. the frequency, duration, localizations and symptoms of headache will be determined with the information obtained as a result of the forms filled in by the participants. the second aim of this study is to examine the effects of headache on physical, social and psychological status in undergraduate student(participants) from a biopsychosocial perspective.

headache is one of the most common nervous system disorders in society. 95 percent of the population has experienced a headache at least once in their life. the one-year prevalence is almost 1 in 2 people. the prevalence of headache increases with age. while there is no difference between the sexes in terms of incidence before adolescence, it is more common in the female population in the post-adolescent period. the icf model, developed by the world health organization, adopts the biopsychosocial approach to provide a holistic perspective. according to this approach, it is aimed to develop interventions by evaluating and examining the biological and psychosocial effects of illness and disability, functionality, needs and demands of the individual. headache is also a disease that should be addressed from a biopsychosocial perspective. therefore, the primary aim of this study was to determine the prevalence of headache in undergraduate students. the frequency, duration, localizations and symptoms of headache will be determined with the information obtained as a result of the forms filled in by the participants. the second aim of this study is to examine the effects of headache on physical, social and psychological status in undergraduate student(participants) from a biopsychosocial perspective.

Eligibility criteria:
inclusion criteria: * having undergraduate education at hacettepe university faculty of physical therapy and rehabilitation. * be over 18 years old. * to know turkish. * volunteer to participate in the study. exclusion criteria: * being over 65 years old. * having any neurological problem except headache. * any additional problems that prevent him from completing the questionnaires and scales. to be

Keywords: headache biopsychosocial migraine psychosocial
prediction model for early biliary stasis after bariatric surgery

Conditions: Obesity; Diabetes; Gallstones; Biliary Stasis

Summary: developing and validating a predictive model to estimate the risk of early biliary stasis following bariatric surgery

this study aims to create and validate a model that predicts the likelihood of early biliary stasis in obese patients following bariatric surgery (sleeve gastrectomy and roux-en-y gastric bypass)

Eligibility criteria:
inclusion criteria: 1. bmi ≥32.5 kg/m2 with one or more obesity-related comorbidities. 2. bmi \>35 kg/m2 without coexisting medical problems 3. complete preoperative and follow-up data. exclusion criteria: 1. other bariatric procedures. 2. contraindications for bariatric surgery.
a multicenter phase 3 study of interferon-beta-1a for the treatment of chronic hepatitis c in asian subjects

Conditions: Hepatitis C

Summary: the main objective of this study is to establish interferon-beta-1a as the treatment of choice for chronic hepatitis c with better efficacy and safety profiles in monotherapy or combination therapy. this will be a multicenter, randomized, double-blind, placebo-controlled study with a placebo to be crossed-over to a combination of interferon-beta-1a and ribavirin or no treatment during an open-label extension phase. the duration of the trial will be 48 weeks, with a double-blind period of 12 weeks. the study will recruit 257 eligible subjects of either sex. it will be conducted by approximately 16 investigators / investigational centers in 3 countries (china, hong kong and singapore).


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * have an elevated serum alanine aminotransferase (alt) between 1.5 and 10 times the upper limit of normal * had adequate bone marrow reserve and organ function * are not pregnant and are willing to use contraception, if, of childbearing potential * are willing and able to comply with the protocol and to give written informed consent * other protocol defined inclusion criteria may apply exclusion criteria: * clinical evidence of liver cirrhosis or a diagnosis of definite cirrhosis on liver biopsy * history of liver failure, severe retinopathy, immunologically mediated disease, cancer or epilepsy with a history of inadequately controlled seizures * any cause for the liver disease other than chronic hepatitis c * evidence of chronic renal impairment, liver cancer, unstable psychiatric disorder, known or ongoing alcohol or drug abuse * positive test at screening for hepatitis b surface antigen, immunoglobulin m hepatitis b core antibody and human immunodeficiency virus antibody * previous systemic treatment for hepatitis c with an interferon or ribavirin * presence of systemic disease that might interfere with subject safety, compliance or evaluation * known allergies to acetaminophen, human serum albumin or mannitol; * glucocorticosteroids or other immunosuppressive drugs taken within 28 days of starting treatment * bearing organ transplants (except cornea) * other protocol defined exclusion criteria may apply

Keywords: subjects with chronic hepatitis c who have never previously received interferon therapy.
adjuvant nivolumab after salvage resection in head and neck cancer patients previously treated with definitive therapy

Conditions: Head and Neck Cancer

Summary: the purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.


Eligibility criteria:
inclusion criteria: * prior definitive therapy with radiation (with or without prior surgical resection and/or chemotherapy) who have underwent salvage resection with curative intent and have no other curable options * pre-operative scans including chest imaging preferably pet/ct and ct neck w/contrast. mri neck is acceptable if contrast contraindicated. * able to provide archived biopsy or resected tissue. * adequate performance status and labs. exclusion criteria: * patients who did not receive at least radiotherapy as prior definitive treatment. * patients who have gross measurable residual disease after surgery or those who underwent surgery for palliative purposes i.e. for symptom control. * has nasopharyngeal or sinonasal carcinoma. * has confirmed metastatic disease.
a study of cd19 targeted car t cell therapy in adult patients with relapsed or refractory b cell acute lymphoblastic leukaemia (all)

Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

Summary: this is a phase ib/ii study to evaluate the safety and efficacy of autologous t cells engineered with a chimeric antigen receptor (car) targeting cd19 in adult patients with relapsed or refractory b cell acute lymphoblastic leukemia (all).

this phase ib/ii, open-label, multi-center, single arm study is designed to evaluate the safety and efficacy of auto1 in adult patients with b-cell all by determining the overall response rate (orr). adult patients with relapsed or refractory all will be enrolled in both phases of the study. consented patients will go through the following five sequential stages: screening, leukapheresis, pre-conditioning, treatment, and follow-up. all patients will receive a total target dose of 410e+6 of car t cells as a split dose on day 1 and on day 10 (± 2 days).

Eligibility criteria:
inclusion criteria: * age 18 years or older age 18 years or older * ecog performance status of 0 or 1 * relapsed or refractory b cell all * patients with ph+ all are eligible if intolerant to tki, failed two lines of any tki, or failed one line of second-generation tki, or if tki is contraindicated * documented cd19 positivity within 1 month of screening * phase ib: primary cohort ia: presence of ≥5% blasts in bm at screening * phase ib: exploratory cohort ib: mrd-positive defined as ≥ 1e-4 and \<5% blasts in the bm at screening * phase ii: primary cohort iia: presence of ≥5% blasts in bm at screening * phase ii: cohort iib: ≥2nd cr or cri with mrd-positive defined as ≥1e-3 by central clonoseq® ngs testing and \<5% blasts in the bm at screening * adequate renal, hepatic, pulmonary, and cardiac function exclusion criteria: * phase ib (cohort ia and cohort ib) and phase ii (cohort iia and cohort iib) b-all with isolated em disease * diagnosis of burkitt's leukaemia/lymphoma or cml lymphoid in blast crisis * history or presence of clinically relevant cns pathology * presence of cns-3 disease or cns-2 disease with neurological changes * presence of active or uncontrolled fungal, bacterial, viral, or other infection requiring systemic antimicrobials for management * active or latent hepatitis b virus or active hepatitis c virus * human immunodeficiency virus (hiv), htlv-1, htlv-2, syphilis positive test * prior cd19 targeted therapy other than blinatumomab. patients who have experienced grade 3 or higher neurotoxicity following blinatumomab.

Keywords: b cell acute lymphoblastic leukemia relapsed b cell acute lymphoblastic leukemia refractory b cell acute lymphoblastic leukemia all auto1 cd19-positive car t cell